Mark Shilkrut, Gregory S. Merrick, P. William McLaughlin, Matthew H. Stenmark, Eyad Abu-Isa, Sean M. Vance, Howard M. Sandler, Felix Y. Feng and Daniel A. Hamstra The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer Cancer 119
Article first published online: 14 AUG 2012 | DOI: 10.1002/cncr.27784
The authors retrospectively analyze the impact of combined-modality radiation therapy on clinical outcomes in 958 patients with high-risk prostate cancer. The addition of an interstitial brachytherapy boost and long-term androgen suppression significantly decreases the rates of biochemical failure and prostate cancer death compared with dose-escalated radiotherapy.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field